New drug duo targets Tough-to-Treat ovarian cancer
NCT ID NCT06617923
Summary
This study is testing whether a combination of two oral drugs, senaparib and temozolomide, can shrink tumors in women with a specific type of recurrent ovarian cancer that has a genetic change called ARID1A. It is for women whose cancer has come back after prior treatments. The main goal is to see how many patients' tumors respond to this new combination and to check its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21231-2410, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania/Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.